New combo offers hope for lung cancer patients after immunotherapy fails
NCT ID NCT05407155
First seen Apr 28, 2026 · Last updated Apr 28, 2026
Summary
This study looks at a combination of three drugs (bevacizumab, nab-paclitaxel, and platinum) as a second treatment for people with a certain type of advanced lung cancer that got worse after initial immunotherapy. The goal is to see if this combo can shrink tumors and help patients live longer. The study involves 56 adults aged 18 to 75 whose cancer has spread and does not have specific genetic mutations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer hospital Fudan University
Shanghai, Shanghai Municipality, 200032, China
Conditions
Explore the condition pages connected to this study.